Cell cycle and cancer

Clinical and Translational Oncology

Volumn 2, Issue 1, 2000, Pages 12-22

  Carnero, Amancio ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; CDK; Cell cycle; Checkpoint; CKI; Cyclin

Indexed keywords

EID: 0005554088     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Morgan DO, De Bondt HL Protein kinase regulation: insights from crystal structure analysis. Curr Opin Cell Biol 1994; 6: 239-246.
2. Kobayashi H, Stewart E, Poon R, Adamczewski JP, Gannon J, Hunt T. Identification of the domains in cyclin A required for binding to, and activation of, p34cdc2 and p32cdk2 protein kinase subunits. Mol Biol Cell 1992; 3: 1279-1294.
3. Lees EM, Harlow E. Sequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinase. Mol Cell Biol 1993; 13: 1194-1201.
4. Pines J, Hunter T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 1989; 58: 833-846.
5. Pines J, Hunter T. Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol 1991; 115: 1-17.
6. Lew DJ, Dulic V, Reed SI. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 1991; 66: 1197-1206.
7. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 1992; 11: 3995-4005.
8. Kato JY, Matsuoka M, Strom DK, Sherr CJ. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activa-ting kinase. Mol Cell Biol 1994; 14: 2713-2721.
9. Ducommun B, Brambilla P, Felix MA, Franza BR Jr, Karsenti E, Draetta G. cdc2 phosphorylation is required for its interaction with cyclin. EMBO J 1991; 10: 3311-3319.
10. Clarke PR Cyclin-dependent kinases. CAK-handed kinase activation. Curr Biol 1995; 5: 40-42.
11. Fesquet D, Labbe JC, Derancourt J, Capony JP, Galas S, Girard F et al. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosp-horylation of Thr161 and its homologues. EMBO J 1993; 12: 3111-3121.
12. Poon RY, Yamashita K, Adamczewski JP, Hunt T, Shut-tleworth J. The cdc2-related protein p40MO15 is the catalytic subunit of a protein kinase that can activate p33cdk2 and p34cdc2. EMBO J 1993; 12: 3123-3132.
13. Fisher RP, Morgan DO. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 1994; 78: 713-724.
14. Parker LL, Piwnica-Worms H. Inactivation of the p34-cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992; 257: 1955-1957.
15. McGowan CH, Russell P. Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 1993; 12: 75-85.
16. Coleman TR, Tang Z, Dunphy WG. Negative regulation of the wee1 protein kinase by direct action of the nim1/cdr1 mitotic inducer. Cell 1993; 72: 919-929.
17. Tang Z, Coleman TR, Dunphy WG. Two distinct mechanisms for negative regulation of the Wee1 protein kinase. EMBO J 1993; 12: 3427-3436.
18. Russell P, Nurse P. cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell 1986; 45: 145-153.
19. Galaktionov K, Beach D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 1991; 67: 1181-1194.
20. Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J 1994; 13: 4302-4310.
21. Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Noji-ma H et al. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J 1994; 13: 1549-1556.
22. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-1163.
23. Carnero A, Hannon GJ. The INK4 family of CDK inhibitors Curr Top Microbiol Immunol 1998; 227: 43-55.
24. Hengst L, Reed SI. Inhibitors of the Cip/Kip family. Curr Top Microbiol Immunol 1998; 227: 25-41.
25. Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res 1997; 237: 7-13.
26. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
27. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
28. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90-98.
29. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A et al. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024-1027.
30. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995; 9: 935-944.
31. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kina-se and PCNA. Nature 1995; 374: 386-388.
32. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.
33. Afshari CA, Nichols MA, Xiong Y, Mudryj M. A role for a p21-E2F interaction during senescence arrest of normal human fibroblasts. Cell Growth Differ 1996; 7: 979-988.
34. Dimri GP, Nakanishi M, Desprez PY, Smith JR, Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol 1996; 16: 2987-2997.
35. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
36. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
37. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
38. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996; 271: 1861-1864.
39. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI. A cell cycle-regulated inhibitor of cyclin-dependent kina-ses. Proc Natl Acad Sci USA 1994; 91: 5291-5295.
40. Agrawal D, Hauser P, McPherson F, Dong F, García A, Pledger WJ. Repression of p27kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. Mol Cell Biol 1996; 16: 4327-4336.
41. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V et al. Role of the ubiquitin-proteaso-me pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-685.
42. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995; 9: 650-662.
43. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
44. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994. 371: 257-261.
45. Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16INK4. Mol Cell Biol 1995; 15: 2682-2688.
46. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995; 15: 2672-2681.
47. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
48. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12: 2984-2991.
49. ARF act in overlapping pathways (submitted).
50. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 1996; 93: 13742-13747.
51. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
52. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995; 9: 1831-1845.
53. Reynisdottir I, Massague J. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997; 11: 492-503.
54. Lu KP, Hunter T. Evidence for a NIMA-like mitotic pathway in vertebrate cells. Cell 1995; 81: 413-442.
55. Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73: 1059-1065.
56. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994; 79: 551-555.
57. Mittnacht S, Lees JA, Desai D, Harlow E, Morgan DO, Weinberg RA. Distinct sub-populations of the retino-blastoma protein show a distinct pattern of phosphory-lation. EMBO J 1994; 13: 118-127.
58. Hinds PW, Weinberg RA. Tumor suppressor genes. Curr Opin Genet Dev 1994; 4: 135-141.
59. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
60. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 1997; 272: 12738-12746.
61. Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993; 90: 9026-9030.
62. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994; 14: 1669-1679.
63. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7: 812-821.
64. Medema RH, Herrera RE, Lam F, Weinberg, RA. Growth suppression by p16INK4 requires functional retinoblastoma protein. Proc. Natl. Acad. Aci. USA 1995; 92: 6289-6293.
65. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.Nature 1995; 375: 503-506.
66. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995; 15: 2612-2624.
67. Lukas J, Herzinger T, Hansen K, Moroni MC, Resnitzky D, Helin K et al. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev 1997; 11: 1479-1492.
68. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997; 387: 422-426.
69. Grana X, Garriga J, Mayol X. Role of the retinoblasto-ma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 1998; 17: 3365-3383.
70. Johnson DG, Schneider-Broussard R. Role of E2F in cell cycle control and cancer. Frontiers in Bioscience 1998; 3: 447-458.
71. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245-2262.
72. Wang JY. Retinoblastoma protein in growth suppression and death protection. Curr Opin Genet Dev 1997; 7: 39-45.
73. Fang F, Newport JW. Evidence that the G1-S and G2-M transitions are controlled by different cdc2 proteins in higher eukaryotes. Cell 1991; 66: 731-742.
74. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993; 259: 1908-1912.
75. Girard F, Strausfeld U, Fernandez A, Lamb NJ. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991; 67: 1169-1179.
76. Cardoso MC, Leonhardt H, Nadal-Ginard B. Reversal of terminal differentiation and control of DNA replication: cyclin A and Cdk2 specifically localize at subnuclear sites of DNA replication. Cell 1993; 74: 979-992.
77. D'Urso G, Marraccino RL, Marshak DR, Roberts JM. Cell cycle control of DNA replication by a homologue from human cells of the p34cdc2 protein kinase. Science 1990; 250: 786-791.
78. Ohi R, Gould KL. Regulating the onset of mitosis. Curr Opin Cell Biol 1999; 11: 267-273.
79. Jiang W, Kahn SM, Zhou P, Zhang YJ, Cacace AM, Infante AS et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 1993; 8: 3447-3457.
80. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994; 91: 709-713.
81. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669-671.
82. Xiong Y, Menninger J, Beach D, Ward DC. Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins. Genomics 1992; 13: 575-584.
83. Withers DA, Harvey RC, Faust JB, Melnyk O, Carey K, Meeker TC. Characterization of a candidate bcl-1 gene. Mol Cell Biol 1991; 11: 4846-4853.
84. Donnellan R, Chetty R. Cyclin D1 and human neopla-sia. Mol Pathol 1998; 51: 1-7.
85. Hanna Z, Jankowski M, Tremblay P, Jiang X, Milato-vich A, Francke U et al. The Vin-1 gene, identified by provirus insertional mutagenesis, is the cyclin D2. Oncogene 1993; 8: 1661-1666.
86. Leach FS, Elledge SJ, Sherr CJ, Willson JK, Markowitz S, Kinzler KW et al. Amplification of cyclin genes in colorectal carcinomas. Cancer Res 1993; 53: 1986-1989.
87. Wang J, Chenivesse X, Henglein B, Brechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellu-lar carcinoma. Nature 1990; 343: 555-557.
88. Haas K, Johannes C, Geisen C, Schmidt T, Karsunky H, Blass-Kampmann S et al. Malignant transformation by cyclin E and Ha-Ras correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4. Oncogene 1997; 15: 2615-2623.
89. Donnellan R, Chetty R. Cyclin E in human cancers. FASEB J 1999; 13: 773-780.
90. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M et al. CDC25 phosphatases as potential human oncogenes. Science 1995; 269: 1575-1577.
91. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harsh-man K, Tavtigian SV et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
92. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998; 1378: 115-177.
93. González-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM et al. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55: 4531-4535.
94. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-692.
95. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hemato-logical malignancies. Cancer Res 1997; 57: 837-841.
96. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85: 27-37.
97. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649-659.
98. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995; 375: 506-510.
99. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281-1284.
100. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
101. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995; 377: 552-557.
102. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.
103. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997; 277: 831-834.
104. Mousses S, Ozcelik H, Lee PD, Malkin D, Bull SB, Andrulis IL. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 1995; 4: 1089-1092.
105. Sjalander A, Birgander R, Rannug A, Alexandrie AK, Tornling G, Beckman G. Association between the p21 codon 31 A1 (arg) allele and lung cancer. Hum Hered 1996; 46: 221-225.
106. Terry LA, Boyd J, Alcorta D, Lyon T, Solomon G, Han-non G et al. Mutational analysis of the p21/WAF1/-CIP1/SDI1 coding region in human tumor cell lines. Mol Carcinog 1996; 16: 221-228.
107. Shi Y, Zou M, Farid NR, al-Sedairy ST. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. Br J Cancer 1996; 74: 1336-1341.
108. Balbin M, Hannon GJ, Pendas AM, Ferrando AA, Vizo-so F, Fueyo A et al. Functional analysis of a p21WAF1,-CIP1,SDI1 mutant (Arg94-Trp) identified in a human breast carcinoma. Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. J Biol Chem 1996; 271: 15782-15786.
109. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996; 85: 733-744.
110. Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y et al. An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet 1996; 14: 171-173.
111. Hatada I, Nabetani A, Morisaki H, Xin Z, Ohishi S, Tonoki H et al. New p57KIP2 mutations in Beckwith-Wiedemann syndrome. Hum Genet 1997; 100: 681-683.
112. Lee MP, DeBaun M, Randhawa G, Reichard BA, Elled-ge SJ, Feinberg AP. Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. Am J Hum Genet 1997; 61: 304-309.
113. O'Keefe D, Dao D, Zhao L, Sanderson R, Warburton D, Weiss L et al. Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors. Am J Hum Genet 1997; 61: 295-303.
114. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC et al. Altered cell differentiation and pro-liferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997; 387: 151-158.
115. Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yan-dell DW, Kaye FJ et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 1990; 87: 2775-2779.
116. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-937.
117. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncoge-ne 1994; 9: 3375-3378.
118. Johnson, DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 1994; 91: 12823-12827.
119. Singh, P, Wong S, Hong W. Overexpression of E2F-1 inrat embryo fibroblasts leads to neoplastic transformation. EMBO 1994; 13: 3329-3338.
120. Xu G, Livingston D M, Krek W. Multiple members of the E2F transcription factor family are the products of oncogenes. Proc Natl Acad Sci USA 1995; 92: 1357-1361.
121. Jooss K, Lam W-F, Bybee A, Girling R, Muller R, La Thangue NB. Proto-oncogenic properties of the DP family of proteins. Oncogene 1995; 10: 1529-1536.
122. Beijersbergen RL, Kerkhoven RM, Zhu L, Carlee L, Voorhoeve PM, Bernards R. E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev 1994; 8: 2680-2690.
123. Ginsberg D, Vairo G, Chittenden T, Xiao ZX, Xu G, Wydner K L et al. E2F-4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev 1994; 8: 2665-2679.
124. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 537-548.
125. Field S J, Tsai F-Y, Kuo F, Zubiaga AM, Kaelin WG,. Livingston DM et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549-561.
126. Qin X-Q, Livingston DM, Kaelin Jr. WG, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994; 91: 10918-10922.
127. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 1994; 91: 3602-3606.